Research programme: monoclonal antibodies - Eleven Biotherapeutics

Drug Profile

Research programme: monoclonal antibodies - Eleven Biotherapeutics

Alternative Names: Research programme: Hybridomic monoclonal antibodies - Eleven Biotherapeutics

Latest Information Update: 27 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Viventia Biotech
  • Developer Eleven Biotherapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Sep 2016 Viventia Biotechnologies has been acquired by Eleven Biotherapeutics
  • 07 Feb 2008 Preclinical development is ongoing
  • 18 Mar 2004 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top